Neurosense Therapeutics is trading 7.63% higher at $0.45 after rebounding from its September 8 close of $0.42, with no clear company-specific announcement identified for September 9, 2026.
- Recent volatility followed HC Wainwright’s September 3 Buy initiation and $8 price target, but it does not directly explain the current move.
- Broader U.S. markets are lower, making market sentiment an unlikely explanation for the gain.